Anika Therapeutics Inc. (ANIK) Position Decreased by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL reduced its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 44.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,919 shares of the biotechnology company’s stock after selling 11,356 shares during the period. Tudor Investment Corp ET AL owned 0.09% of Anika Therapeutics worth $687,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue lifted its position in shares of Anika Therapeutics by 79.5% during the second quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 1,272 shares in the last quarter. Mason Street Advisors LLC lifted its position in shares of Anika Therapeutics by 7.1% during the first quarter. Mason Street Advisors LLC now owns 3,423 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 228 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Anika Therapeutics by 68.4% during the first quarter. Victory Capital Management Inc. now owns 3,452 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,402 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Anika Therapeutics by 3.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 100 shares in the last quarter. Finally, Envestnet Asset Management Inc. bought a new position in shares of Anika Therapeutics during the first quarter valued at about $204,000. 84.47% of the stock is currently owned by institutional investors.
In other Anika Therapeutics news, CEO Charles H. Sherwood sold 63,799 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the transaction, the chief executive officer now owns 174,705 shares in the company, valued at approximately $8,873,266.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.57% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Anika Therapeutics Inc. (ANIK) Position Decreased by Tudor Investment Corp ET AL” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/anika-therapeutics-inc-anik-position-decreased-by-tudor-investment-corp-et-al/1617225.html.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 59.54 on Friday. The stock has a market cap of $872.74 million, a P/E ratio of 26.45 and a beta of 1.66. The company’s 50-day moving average is $55.65 and its 200-day moving average is $49.09. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $59.91.
Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.32. The business had revenue of $33.50 million for the quarter, compared to analysts’ expectations of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The business’s revenue for the quarter was up 25.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.57 EPS. On average, equities research analysts anticipate that Anika Therapeutics Inc. will post $2.20 earnings per share for the current year.
A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.